Annual EBITDA:
-$426.72M-$119.09M(-38.71%)Summary
- As of today, RXRX annual EBITDA is -$426.72 million, with the most recent change of -$119.09 million (-38.71%) on December 31, 2024.
- During the last 3 years, RXRX annual EBITDA has fallen by -$251.60 million (-143.67%).
- RXRX annual EBITDA is now -626.27% below its all-time high of -$58.76 million, reached on December 31, 2019.
Performance
RXRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$147.57M+$35.24M(+19.28%)Summary
- As of today, RXRX quarterly EBITDA is -$147.57 million, with the most recent change of +$35.24 million (+19.28%) on June 30, 2025.
- Over the past year, RXRX quarterly EBITDA has dropped by -$58.87 million (-66.37%).
- RXRX quarterly EBITDA is now -758.65% below its all-time high of -$17.19 million, reached on March 31, 2020.
Performance
RXRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$583.64M-$58.87M(-11.22%)Summary
- As of today, RXRX TTM EBITDA is -$583.64 million, with the most recent change of -$58.87 million (-11.22%) on June 30, 2025.
- Over the past year, RXRX TTM EBITDA has dropped by -$235.29 million (-67.54%).
- RXRX TTM EBITDA is now -3296.03% below its all-time high of -$17.19 million, reached on March 31, 2020.
Performance
RXRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RXRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -38.7% | -66.4% | -67.5% |
| 3Y3 Years | -143.7% | -135.1% | -161.2% |
| 5Y5 Years | -626.3% | -743.6% | -918.7% |
RXRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -143.7% | at low | -171.9% | +19.3% | -156.4% | at low |
| 5Y | 5-Year | -626.3% | at low | -552.5% | +19.3% | -918.7% | at low |
| All-Time | All-Time | -626.3% | at low | -758.6% | +19.3% | -3296.0% | at low |
RXRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$147.57M(+19.3%) | -$583.64M(-11.2%) |
| Mar 2025 | - | -$182.81M(-10.6%) | -$524.77M(-23.0%) |
| Dec 2024 | -$426.72M(-38.7%) | -$165.34M(-88.1%) | -$426.72M(-21.6%) |
| Sep 2024 | - | -$87.92M(+0.9%) | -$350.86M(-0.7%) |
| Jun 2024 | - | -$88.70M(-4.7%) | -$348.35M(-5.3%) |
| Mar 2024 | - | -$84.75M(+5.3%) | -$330.81M(-7.5%) |
| Dec 2023 | -$307.63M(-35.1%) | -$89.48M(-4.8%) | -$307.63M(-12.9%) |
| Sep 2023 | - | -$85.41M(-20.0%) | -$272.42M(-11.4%) |
| Jun 2023 | - | -$71.16M(-15.6%) | -$244.45M(-3.6%) |
| Mar 2023 | - | -$61.58M(-13.5%) | -$236.05M(-3.7%) |
| Dec 2022 | -$227.66M | -$54.27M(+5.5%) | -$227.67M(+3.6%) |
| Sep 2022 | - | -$57.44M(+8.5%) | -$236.12M(-5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$62.76M(-18.0%) | -$223.45M(-12.1%) |
| Mar 2022 | - | -$53.20M(+15.2%) | -$199.25M(-13.8%) |
| Dec 2021 | -$175.12M(-114.3%) | -$62.72M(-40.1%) | -$175.12M(-28.0%) |
| Sep 2021 | - | -$44.77M(-16.1%) | -$136.82M(-19.3%) |
| Jun 2021 | - | -$38.57M(-32.7%) | -$114.66M(-22.5%) |
| Mar 2021 | - | -$29.07M(-19.1%) | -$93.58M(-14.5%) |
| Dec 2020 | -$81.70M(-39.1%) | - | - |
| Dec 2020 | - | -$24.41M(-7.9%) | -$81.70M(-42.6%) |
| Sep 2020 | - | -$22.61M(-29.3%) | -$57.29M(-65.2%) |
| Jun 2020 | - | -$17.49M(-1.8%) | -$34.68M(-101.8%) |
| Mar 2020 | - | -$17.19M | -$17.19M |
| Dec 2019 | -$58.76M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of RXRX is -$426.72M
What is the all-time high annual EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual EBITDA is -$58.76M
What is Recursion Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, RXRX annual EBITDA has changed by -$119.09M (-38.71%)
What is Recursion Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of RXRX is -$147.57M
What is the all-time high quarterly EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$17.19M
What is Recursion Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, RXRX quarterly EBITDA has changed by -$58.87M (-66.37%)
What is Recursion Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of RXRX is -$583.64M
What is the all-time high TTM EBITDA for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM EBITDA is -$17.19M
What is Recursion Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, RXRX TTM EBITDA has changed by -$235.29M (-67.54%)